Voyager Therapeutics, Inc.
NASDAQ:VYGRBiotechnology
Healthcare
$1.67 +2.35%
+$0.09 today
- Market cap
- $103.92M
- Beta
- 1.25
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$1.96
52W Low $2.83High $5.55
Volume 0.84M
Average 0.54M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$132.47M
FY 2025 · Annual
Investing Cash Flow
$125.45M
FY 2025 · Annual
Financing Cash Flow
$816,000.00
FY 2025 · Annual
-99.3% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.2M) | (46.41M) | 132.33M | (65M) | (119.72M) |
| Depreciation & Amortization | 5.17M | 6.19M | 4.44M | 4.73M | 4.06M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 11.32M | 9.34M | 11.15M | 14.79M | 14.79M |
| Change in Working Capital | 3.29M | 20.47M | (66.56M) | 34.86M | (28.76M) |
| Accounts Receivables | 7.28M | 475K | (83.23M) | 81.31M | 268K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (60K) | 1.99M | (962K) | 2.39M | 1.02M |
| Other Working Capital | (3.93M) | 18M | 17.64M | (48.84M) | (30.05M) |
| Other Non-Cash Items | (2.11M) | (2.11M) | (3.45M) | (4.68M) | (2.83M) |
| Operating Cash Flow | (53.53M) | (12.51M) | 77.92M | (15.31M) | (132.47M) |
| Capital Expenditures | (1.61M) | (2.49M) | (3.26M) | (3.52M) | (2.6M) |
| Acquisitions (Net) | 0 | 0 | 138.39M | 0 | 0 |
| Purchases of Investments | (15.12M) | (54.85M) | (223.97M) | (465.69M) | (133.93M) |
| Sales of Investments | 82.63M | 50M | 85.58M | 374.35M | 261.97M |
| Other Investing Activities | 0 | 0 | (138.39M) | 0 | 0 |
| Investing Cash Flow | 65.91M | (7.34M) | (141.64M) | (94.86M) | 125.45M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 612K | 1.11M | 33.65M | 114.02M | 816K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 612K | 1.11M | 33.65M | 114.02M | 816K |
| Effect of Forex Changes | 0 | 264K | 0 | 0 | 0 |
| Net Change in Cash | 12.99M | (18.47M) | (30.08M) | 3.85M | (6.21M) |
| Free Cash Flow | (55.13M) | (15M) | 74.66M | (18.83M) | (135.06M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$119.7M
+ D&A$4.1M
+ Stock-Based Comp$14.8M
+ Deferred Tax$0
- Working Capital-$28.8M
- Other Non-Cash-$2.8M
= Operating Cash Flow-$132.5M
- Capex-$2.6M
= Free Cash Flow-$135.1M
Analysis
FY2025 free cash flow is -$135.1M. FCF conversion is 112.8% of net income. Operating cash flow was -$132.5M, with capex of -$2.6M. The largest bridge item is Working Capital at -$28.8M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 | |
| 8-K | Current report | Oct 21, 2026 |
Does VYGR generate free cash flow?
Voyager Therapeutics, Inc. (VYGR) generated -$135.06M of free cash flow in fiscal 2025.
How much operating cash flow does VYGR produce?
Operating cash flow was -$132.47M, before capital expenditures of $2.60M.
Continue the stock analysis
Jump to another research area for this company.